PXS-4728 by Syntara for Sleep Disorders: Likelihood of Approval

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Climate change policies neglect children’s mental health and specific needs, study reveals

A recent study highlights the critical need for child-specific adaptation measures in climate change policies, revealing significant gaps in addressing children’s health and mental well-being.

June 7, 2024

Can a machine learning model accurately predict autism spectrum disorder?

A novel ML algorithm (named ‘AutMedAI’) capable of early autism spectrum disorder (ASD) detection with minimal background and medical information.

August 22, 2024

Combined scanning technique could refine treatment for early-stage breast cancer patients

Using a combined scanning technique on patients with early-stage breast cancer improved treatment in almost three out of ten cases in a trial presented at

March 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.